Uterine Cancer

Cells were treated with 20 μM hydrogen peroxide (H2O2) for 4 days, and physicochemical properties of Exos were analyzed using dynamic light scattering (DLS), scanning electron microscope (SEM), and western blotting. The expression of genes such as ALIX, CD63, TSG101, Rab27a, and Rab27b, along with aging factor senescence-associated

Eosinophilic globules, staghorn-like vessels and diffuse nuclear atypia have been shown to have high diagnostic value and could be considered morphologic indicators of dFH-LMs. The substantial interobserver reproducibility of eosinophilic globules makes this feature particularly promising for routine clinical practice.

These cases expand the landscape of FOXO1-rearranged neoplasms and describe a potential new uterine mesenchymal entity. Further study of additional cases is needed to establish whether these rearrangements truly represent an initiating event for a distinct subset of uterine sarcomas, or whether FOXO1 rearrangements simply represent an additional noninitiating/nondriver event within other established tumor types.

This spatial organization suggests their involvement in intercellular communication and stromal coordination within the ovarian microenvironment. These findings provide the first ultrastructural and immunohistochemical evidence of telocytes in the human ovarian stroma and highlight the need for further studies to clarify their physiological and pathological roles in ovarian function, including potential morphological and molecular differences among females of different age groups.

P1, N=6, Active, not recruiting, University Health Network, Toronto | N=24 --> 6 | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Oct 2025

P1/2, N=764, Recruiting, Genmab | N=569 --> 764

P=N/A, N=22, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

P=N/A, N=56, Recruiting, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | Not yet recruiting --> Recruiting

P=N/A, N=42, Not yet recruiting, Assiut University

P2, N=23, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Nov 2026

P1/2, N=54, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Sep 2026 --> Jul 2027

This case underscores the diagnostic complexity of TFE3-rearranged PEComas, which can lack smooth muscle marker expression and mimic other high-grade uterine malignancies. Recognition of the nested vascular arrangement and utilization of melanocytic and TFE3 markers are key for diagnosis.